Search results for "RESISTANCE"

showing 10 items of 3641 documents

Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment

2014

Cancer is one of the most urgent health issues of today. According to WHO, the number of cancer cases is expected to increase by 75% in the next two decades (1). Despite some remarkable achievements in the fields of cancer prevention and early detection, the goal of developing effective anti-cancer therapies still remains unmet. Tumor recurrence due to treatment resistance is the most common cause of death from cancer. Delineating cellular and molecular mechanisms underlying tumor recurrence is of prime importance for the ability to improve the efficacy of existing therapies and develop new strategies to cancer treatment.

cancer stem cellsCancer Researchmedicine.medical_specialtytumor clones selectionEarly detectionintratumor heterogeneityBioinformaticslcsh:RC254-282Intratumor heterogeneityCancer stem cellmedicinecancerTreatment resistanceIntensive care medicineCancer preventionbusiness.industryintratumor spatiotemporal patternsCancerOpinion Articlelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetumor recurrenceCancer treatmentTumor recurrenceOncologybusinessanti-cancer therapyFrontiers in Oncology
researchProduct

MicroRNA-29b-1 impairs in vitro cell proliferation, self‑renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells

2014

Osteosarcoma (OS) is the most common type of bone cancer, with a peak incidence in the early childhood. Emerging evidence suggests that treatments targeting cancer stem cells (CSCs) within a tumor can halt cancer and improve patient survival. MicroRNAs (miRNAs) have been implicated in the maintenance of the CSC phenotype, thus, identification of CSC-related miRNAs would provide information for a better understanding of CSCs. Downregulation of miRNA-29 family members (miR-29a/b/c; miR‑29s) was observed in human OS, however, little is known about the functions of miR-29s in human OS CSCs. Previously, during the characterization of 3AB-OS cells, a CSC line selected from human OS MG63 cells, we…

cancer stem cellsHomeobox protein NANOGCancer Research3AB-OS cells; Cancer stem cells; MicroRNA; MicroRNA-29b-1; Multidrug resistance; Osteosarcoma; Bone Neoplasms; Cell Line Tumor; Cell Movement; Cell Proliferation; Drug Resistance Neoplasm; Gene Expression Regulation Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Osteosarcoma; Cancer Research; OncologyDrug ResistanceBone NeoplasmsBiologyCell LineSOX2multidrug resistanceCell MovementCancer stem cellCell Line TumorSettore BIO/10 - BiochimicamicroRNAmedicineHumansNeoplasm InvasivenessClonogenic assaymicroRNA-29b-1Cell ProliferationNeoplasticOsteosarcomaTumormicroRNAOncogeneCancer3AB-OS cellsArticlesCell cyclemedicine.diseaseGene Expression Regulation Neoplasticosteosarcoma cancer stem cells microRNA microRNA-29b-1 multidrug resistance 3AB-OS cellsMicroRNAsGene Expression RegulationOncologyDrug Resistance NeoplasmImmunologyCancer researchNeoplasm
researchProduct

GSK-3 as potential target for therapeutic intervention in cancer

2014

// James A. McCubrey 1 , Linda S. Steelman 1 , Fred E. Bertrand 2 , Nicole M. Davis 1 , Melissa Sokolosky 1 , Steve L. Abrams 1 , Giuseppe Montalto 3 , Antonino B. D’Assoro 4 , Massimo Libra 5 , Ferdinando Nicoletti 5 , Roberta Maestro 6 , Jorg Basecke 7,8 , Dariusz Rakus 9 , Agnieszka Gizak 9 Zoya Demidenko 10 , Lucio Cocco 11 , Alberto M. Martelli 11 and Melchiorre Cervello 12 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC, USA 2 Department of Oncology, Brody School of Medicine at East Carolina University Greenville, NC, USA 3 Biomedical Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy …

cancer stem cellsNotchmedicine.medical_treatmentReviewmacromolecular substancesPI3KTargeted therapyGlycogen Synthase Kinase 3GSK-3Cancer stem cellNeoplasmsmedicinePTENAnimalsHumansRapamycinProtein kinase BPI3K/AKT/mTOR pathwayGSK-3; cancer stem cells; Wnt/beta-catenin; PI3K; Akt; mTOR; Hedgehog; Notch; Targeted Therapy; Therapy Resistance; Mutations RapamycinGSK-3Roswell Park Cancer InstitutebiologyAkt; Cancer stem cells; GSK-3; Hedgehog; MTOR; Mutations; Notch; PI3K; Rapamycin; Targeted therapy; Therapy resistance; Wnt/beta-cateninAnimalAktWnt/beta-cateninCancerTargeted TherapyTherapy Resistancemedicine.disease3. Good healthOncologybiology.proteinCancer researchmTORHedgehogMutationsHuman
researchProduct

Natural anti-oxidants immobilized onto carbon nanotubes for thermo-oxidation resistant polymer-based nanocomposites

2014

carbon nanotubes thermo-oxidation resistanceUHMWPECarbon nanotubespolymer-based nanocompositesNatural anti-oxidantalpha tocopherolquercitinstabilization
researchProduct

Overcoming Imatinib resistance using CAI, a calcium-mediated signal transduction inhibitor: A new therapeutic strategy for chronic myelogenous leucem…

2008

carboxyamdotriazoleImatinib resistanceChronic Myelogenous Leukemia
researchProduct

carboxyamidotriazole-orotate inhibits the growth of imatinib resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis

2012

The Bcr/Abl kinase has been targeted for the treatment of chronic myelogenous leukaemia (CML) by imatinib mesylate. Although more common in solid tumors, increased microvessel density was also reported in chronic myelogenous leukaemia and was associated with a significant increase of angiogenic factors, suggesting that vascularity in haematologic malignancies is a controlled process and may play a role in the leukaemogenic process thus representing an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is the orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor that in vitro has been shown to possess antileukaemic activities (1…

carboxyamidotriazole-orotateimatinib resistance
researchProduct

Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atheroscle…

2022

BACKGROUND AND OBJECTIVE: we have examined the concentration of serum uric acid and the serum uric acid/creatinine ratio as well as their correlations with the main determinants of the hemorheological profile in a group of subjects with subclinical carotid atherosclerosis. METHODS: we evaluated the concentration of serum uric acid and the serum uric acid/creatine ratio in 43 men and 57 women [median age 66.00 (25)] with subclinical carotid atherosclerosis, subsequently divided according to the number of traditional cardiovascular risk factors and to the insulin resistance degree. RESULTS: serum uric acid, but not the serum uric acid/creatinine ratio, results strongly influenced by the numbe…

cardiovascular risk factorsCarotid Artery DiseasesMalePhysiologyurate-lowering therapyhemorheological determinantsnutritional and metabolic diseasesHematologyHyperuricemiaurologic and male genital diseasesuric acid to creatinine ratioUric AcidRisk FactorsPhysiology (medical)CreatinineHumansFemaleInsulin ResistanceCardiology and Cardiovascular MedicineAgedClinical hemorheology and microcirculation
researchProduct

Effects of exercise on life quality in a rheumatoid arthritis patient

2020

Rheumatoid arthritis (RA) is a chronic-degenerative disease characterized by symptoms that significantly impact on the functional capacity and thus, the ability to carry out daily functional activities reducing the quality of life (QoL). The aim was to evaluate the effects of a strength and conditioning (S&C) program on the quality of life (QoL), the self-perception disease impact, the self-fatigue perception and cardiovascular risk factors in a patient with rheumatoid arthritis (RA) and cardiovascular disease (CVD). 34-year-old woman (height: 1.40m; weight: 36.1kg) diagnosed with RA and CVD underwent a six-month S&C program with aerobic training 2-3 times a week in 1-3 sets of 5-15 minutes…

cardiovascular risk factorslcsh:Sportsmedicine.medical_specialtyexercisebusiness.industryCardiovascular risk factorsLife qualityResistance trainingOsteoarthritismedicine.diseaseosteoarthritislcsh:GV557-1198.995Rheumatoid arthritisPhysical therapymedicineresistance traininglcsh:Sports medicinebusinesslcsh:RC1200-1245Spor Hekimligi Dergisi
researchProduct

Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance.

2015

Renal dysfunction is an independent predictor for cardiovascular morbidity and mortality. We investigated whether chronic hepatitis C virus (HCV) infection and the related insulin resistance/hyperinsulinemia influence renal function in comparison with a group of healthy subjects and with another group with metabolic syndrome. We enrolled 130 newly diagnosed HCV outpatients matched for age and gender with 130 patients with metabolic syndrome and 130 healthy subjects. Renal function was evaluated by calculation of glomerular filtration rate (e-GFR, mL/min/1.73 m2) using the CKD-EPI equation. The following laboratory parameters were measured: fasting plasma glucose and insulin, total, LDL- and…

cardiovascular riskMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentRenal function030204 cardiovascular system & hematologyurologic and male genital diseasesKidney Function Testschronic C hepatitis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceChronic C hepatitis Renal function Insulin resistance Cardiovascular risk Metabolic syndromeInternal medicineInternal MedicinemedicineHyperinsulinemiaHumansMetabolic SyndromeCreatinineTriglyceridebusiness.industryInsulinrenal functionCase-control studyHepatitis C ChronicMiddle Agedmedicine.diseaseEndocrinologychemistryCase-Control Studieschronic C hepatitis; renal function; insulin resistance; cardiovascular risk; metabolic syndromeEmergency Medicine030211 gastroenterology & hepatologyFemaleMetabolic syndromeInsulin ResistancebusinessBiomarkersGlomerular Filtration RateInternal and emergency medicine
researchProduct

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes

2022

The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and cardiovascular outcomes. Dietary Free Fatty Acids (FFA) regulate metabolic and anti-inflammatory processes through their action on incretins. Selective synthetic ligands for FFA1-4 receptors have been developed as potential treatments for T2DM. To comprehensively review the available evidence for the potential role of FFA receptor agonists in the treatment of T2DM, we performed an electronic database search assessing the association between FFAs, T2DM, i…

cardiovascular riskMedicine (General)Cardiovascular risk Free fatty acidsGLP-1 Incretins Metabolism Type 2 diabetes Fatty Acids Nonesterified Humans Diabetes Mellitus Type 2 Insulin Resistanceendocrine system diseasesfree fatty acidsType 2 diabetesReviewGeneral MedicineFatty Acids NonesterifiedR5-920Diabetes Mellitus Type 2HumansInsulin ResistanceGLP-1metabolismincretinsMedicina
researchProduct